DMC Group LLC Sells 819 Shares of Novo Nordisk A/S $NVO

DMC Group LLC lowered its position in Novo Nordisk A/S (NYSE:NVO) by 7.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,336 shares of the company’s stock after selling 819 shares during the period. DMC Group LLC’s holdings in Novo Nordisk A/S were worth $713,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Copeland Capital Management LLC boosted its holdings in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after purchasing an additional 255 shares during the last quarter. North Capital Inc. bought a new stake in Novo Nordisk A/S in the first quarter worth about $27,000. Stone House Investment Management LLC bought a new stake in shares of Novo Nordisk A/S during the first quarter worth $30,000. Disciplina Capital Management LLC lifted its holdings in Novo Nordisk A/S by 162.3% during the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after buying an additional 297 shares in the last quarter. Finally, Spirit of America Management Corp NY bought a new stake in Novo Nordisk A/S during the 1st quarter valued at $35,000. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on NVO. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. BNP Paribas raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 13th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Novo Nordisk A/S in a research note on Saturday, September 27th. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Finally, Berenberg Bank upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $77.50.

Novo Nordisk A/S Trading Down 0.9%

Shares of NVO stock opened at $59.10 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The firm has a market cap of $263.90 billion, a PE ratio of 16.24, a price-to-earnings-growth ratio of 2.66 and a beta of 0.68. The company has a 50-day moving average of $54.84 and a two-hundred day moving average of $63.48. Novo Nordisk A/S has a 1-year low of $45.05 and a 1-year high of $120.56.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. On average, analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a $0.4119 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 22.53%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.